Table 1.
Participant Characteristics Overall and By Race and Sex Year 25, 2010 to 2011, n=3011
| All | Black men | Black women | White men | White women | |
|---|---|---|---|---|---|
| Sample size | 3011 | 562 | 852 | 735 | 862 |
| Age, y | 50.1±3.6 | 49.3±3.8 | 49.5±3.8 | 50.6±3.4 | 50.7±3.4 |
| Education attained, y | 15.4±2.5 | 14.2±2.2 | 14.7±2.2 | 16.2±2.6 | 15.4±2.5 |
| Current cigarette smoking | 517 (17.2) | 155 (27.6) | 166 (19.5) | 91 (12.4) | 105 (12.2) |
| Systolic blood pressure, mm Hg | 119.6±15.9 | 125.8±14.6 | 123±17.3 | 119.5±13.4 | 112.3±14.5 |
| Diastolic blood pressure, mm Hg | 74.9±11.1 | 78.6±10.9 | 78.1±11 | 74.3±10 | 70±10.4 |
| Antihypertensive medication | 773 (25.7) | 176 (31.3) | 334 (39.2) | 141 (19.2) | 122 (14.2) |
| Body mass index, (kg/m2) | 30.2±7.1 | 30.1±6.3 | 33.3±7.9 | 28.9±5 | 28.3±7.2 |
| Total cholesterol, mg/dL | 193.3±36.6 | 187.6±37 | 191.9±38.5 | 193±35.9 | 198.8±34.2 |
| HDL cholesterol, mg/dL | 58.3±18.1 | 53.1±16.3 | 61.4±17.3 | 49.6±14.3 | 65.9±18.8 |
| Triglycerides, mg/dL | 114.1±85.8 | 113.3±72.7 | 97.7±72 | 144.4±118.7 | 104.9±63.5 |
| Cholesterol‐lowering medication | 431 (14.3) | 82 (14.6) | 138 (16.2) | 129 (17.6) | 82 (9.5) |
| Diabetes | 392 (13) | 101 (18) | 151 (17.7) | 75 (10.2) | 65 (7.5) |
| eGFR, mL/min/1.73 m2 | 96.3±16.1 | 98.1±18.4 | 102.8±17.8 | 92.1±12.5 | 92.3±12.6 |
| Incident CVD | 106 (3.5) | 32 (5.7) | 31 (3.6) | 29 (4.0) | 14 (1.6) |
| Incident CHD | 55 (1.8) | 16 (2.9) | 11 (1.3) | 23 (3.1) | 5 (0.6) |
| Incident stroke | 39 (1.3) | 11 (2.0) | 15 (1.8) | 4 (0.5) | 9 (1.0) |
| Incident heart failure | 19 (0.6) | 10 (1.8) | 7 (0.8) | 2 (0.3) | 0 (0.0) |
Cells show Mean±SD or n (%).
Abbreviations: eGFR indicates estimated glomerular filtration rate; CVD, cardiovascular disease; and CHD, coronary heart disease.
Note that each individual may qualify for more than one CVD subtype (CHD, stroke, and heart failure). Incident disease in the bottom 4 rows occurred Year 25 in 2010–11 and end of follow‐up, August 31, 2019.